of to and I'd his is past and my over recognition to the many congratulating start Metzger, here of to Syndax. his and of comments his fortunate the I to appointment Officer to today's the Board Thank President you, Michael have with and work an everyone us like four Board importance of appointment joining been the of on years future Melissa. to company. Operating his Directors our important Syndax webcast. Michael at our on by call Chief you thank And accomplishments
high-level cancer which summary and as realize for longer selective from priorities, corporate ever better to with news cleared in people was the has Menin SNDX-XXXX. The inhibitor than a of IND second our provides highly live the future we our the exciting that three Slide current quarter rationally designed our FDA strive before.
we I length in our of are As exciting HERX entinostat cancer. a specific a hormone Class chapter receptor-positive X evolution now new trial accomplishment, inhibitor about the our entinostat HDAC result in at of negative spoken breast We've of and Phase and this entering Syndax. ongoing
to acute takes defined Both The important potential the new our into SNDX-XXXX us become leukemias have treatment program the genetically and importantly portfolio. programs medicine. new broadens of
know about the XX of much We XX months. prospects to and more the future next expect both entinostat to SNDX-XXXX over
versus exemestane Let's trial Slide summarizes review and HERX exemestane XXX this trial plus these cancer. of is plus has receptor-positive of of focus Phase entinostat in randomized patients design clearly placebo breast negative hormone opportunities on trial in X detail. the overall four The entinostat to survival. the now the greater
breast receptor-positive us United special the regulatory upon would for study, designation in protocol approval assessment cancer the six interim analyses by previous our the events approximately States OS conducted upon allow these hormone positive final interim board As are of terms of file metastatic of conclude OS months. to Data any Safety noted the ECOG number at Monitoring calls with the and breakthrough therapy based we've analyses outcome FDA. every to or the on needed in achieving A
ECOG. a regulatory of from receiving within positive, about the six be should is team filing, to trial data Our prepared months submit the
survival. possibility the to trial is like a that a the there as XXX currently I'd of remind uncertain. that will timing analysis either first be futility in trial believe possibility at positive, the once significant analysis both everyone is on that the are overall XXXX. this which well interim, interim formal the November this is of year each futile through conducted events, as readout that based trial evaluates A of will analysis trial the statistically each half of or fully the in We improvement final
first-line the aromatase agent or given the as entinostat/exemestane the is with CDKX/X emphasizes typically inhibitor. after agent combination five regimen potential to in either for a inhibitor Slide be single preferred which a a
patients the of post trial. relevant the received CDKX/X will that prior is we Thus, CDKX/X the Our between and estimate have should inhibitor XX% dataset in a population. EXXXX current have highly in entering XX% to a
expect with similar population our to therapies. after CDKX/X and estimated of adoption the eligible could and entinostat XX,XXX each outcomes substantial patients a on we the therapy positive therapy such This of first-line go of therefore hormone Ibrance in an underscores the would who EXXXX rapid the of with receive anti-estrogen receive In enjoy In widespread to setting physicians inhibitor first-line as improve be to use. the to result, is entinostat opinion, associated who year patients setting failing desire patients regimen. the
rearrangement. predictive a that fusion make proteins between clearance alteration medicines targeted SNDX-XXXX. as news second Let of this detail the provide cancer therapies and Slide genomic our because a me are in result our clinical type agent six for genetically-targeted Menin success now highly against that chromosomal are other similarity the shows IND the quarter, been of comparison and of used has recent more program of the the attack of rearrangements We chromosomal about the them.
was of example protein. The inhibitors BCR-ABL the BCR-ABL results chromosomal protein. and so-called Gleevec treatment fusion oncology harbor other leukemias of Philadelphia in fusion the transformed rearrangement in chromosome, have the recurring that first this which CML
these evidence RET define there translocations, rapid that then, that clinical cell. precisely chromosomal developments to the development fusions been to In chromosomal like cancer fusion populations medicines led is NTRK treatment many medicines path. the Since from driving fusion. have a medicines enabled effects strong a translocation is attack of fusions, result patient these proteins specifically able specific demonstrate examples Being there and of including that regulatory ALK and in and protein large patients fusion resulting the that
be protein an noted examples kinase MLL the just may a fact the should were fusion activated and and in kinase distinct that in was is biology drugs the that SNDX-XXXX kinase Signaling of It resulting I mentioned inhibitor. were not inhibitors. developed rearrangement be
XXXX rearrangement we fusion a drive is a of upon targeted known specific So, to -- the protein a upon how behaves Nonetheless, our clinic. was example leads that understanding to leukemic program our process. to based of need an designed the course in XXXX of see that specific chromosomal therapy
first slide trial accelerated On X, Menin AUGMENT understanding the we in-human summarize our inhibition, in the of program.
I and Phase Phase SNDX-XXXX. II dose Phase a either portion Phase daily tolerated unacceptable and a relapse combined dose mouth leukemia has experience take they II trial clinical in-human maximum enrolled is by trial. escalation for trial will Patients designed recommended until I acute the first dose and or The refractory be or to progressive The SNDX-XXXX with identify will toxicity. disease
order study. which XX Phase escalation. the to days specific for required period in are determining safety Patients of the evaluated abnormalities The I is have to dosing not in serve genetic dose will as in enroll first
a dose follow convert standard toxicity of an with the first X+X level to design. patient accelerated one The pre-specified cohort. per trial required only Upon will a titration cohorts entering
and assess We will safety carefully efficacy. pharmacokinetics,
want of XX I upwards that that precise patients number toxicities anticipated Phase number cohorts is to to be the that PK enrolled trial. is portion It dependent key the and I the may component encountered. are that with the the need analysis I explored of in a on the of Phase be emphasize
Menin-MLLr Our preclinical indicates achieve be needs data in interaction to continuously that to order efficacy. optimal the inhibited
as assess we coverage. be in We seeing are indeed inform patients in the leukemia likelihood And data drug data the those significantly and in of will forward this to the carefully initial so, and look whether single-agent MLL-rearranged NPMX population. target achieving the we dose timing will first efficacy PK to mutant exposures examining adequate cohorts
to we a PK efficacy Phase the believe patients to of exploratory the portion abnormality specific X efficacy objective. than from that informative that the portion being assessments an in data have be required the are Given more X trial, enroll could order in not Phase genetic with
as believe X of the Phase establishing the established coverage adults an X acute myeloid Phase the characterize the efficacy that response will NPMX MLLr Once of Phase the Phase trial in with three or or AML; the dose estimate or to of and achieving which genetically-defined trial complete rate well X bode refractory portion. the of for MLLr leukemia provide adults in leukemia adults will with are a ALL; target proceed the therapeutic acute cohorts cohorts benefit. will Furthermore, further could SNDX-XXXX X portion we and each initial enroll The adequate mutant acute is expansion recommended specific safely lymphoid relapse Phase with AML. primary of three X distinct consists measure safety The leukemia.
know We the investors people, lot to this and data physicians a see including are initial that eager AUGMENT patients, first trial. of from
provide will trial when it getting we as Given the guidance are up just running possible not we and specific that is to present to data.
in able to presenting data underway. to As do the should once not from data of XXXX timing, is be of initial better expect and trial clinical give the a we year. now, anticipate trial data this report We sense you
a population. key molecule our component In to advance strategy. into It addition, of this we overall are eager pediatric is the
say the to of the on details of and underlying a and Based of are expecting pediatric biology more We approach activity. evidence the upon will the about future we data preclinical have timing call. single-agent pathway,
for similar with to IDHX could be mutations. path taken or As result, addressing there rapid a perhaps agents and clinical the XXXX FLTX straightforward development path a patients for
an learn leukemia As for this we of acute the more additional see driver in about and to we Syndax. molecule important SNDX-XXXX potential becoming continue value
turn antibody a a cell testing the GvHD. conducting XXXX cells transplantation potential We're chronic of to and and Chronic is wherein X contribute monotherapy GvHD the and trial best-in-class of disease complication now of me manifestation stem slide CSF-X hematopoietic monoclonal development SNDX-XXXX therapy advanced many the immune to in frequent our receptor. fibrosis as initiation donor-derived Let of targeting symptoms.
interaction of CSF-X/CSF-XR versus antibody an donor in chronic the believe chronic an reducing preventing host with of We XXXX. disease. that result attractive represents disease blockage opportunity and graft anti-CSF-XR host thereby models graft for the clinical pre-clinical depletion macrophages can In versus
patients steroids study, whose When after had our limit to disease ibrutinib progressed enrollment we both required IND and therapy. cleared this for was that FDA
However, currently later population hope anticipated. update half on for of slower to year. as this despite enrollment has used in second the is program We an provide this our frequently treat this year than guidance been not earlier to ibrutinib next
We to pipeline our expand will through we slide X programs. Finally, transactions the summarizes Menin-MLLr acquisition the continue be the that acquisition and to to of that believe led SNDX-XXXX able or compounds these and in-licensing of We preferred valuable we have remain assets. that inflection such to believe necessary bring points clinical differentiated of among development partners transaction. to to the quality expertise expect
will turn Rick call financial to review the over to I now our results.
